Pfizer Inc. (NYSE:PFE) is one of the best affordable healthcare stocks to buy now. Scotiabank analyst Louise Chen reiterated ...

The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and ...

A patient died after receiving Pfizer Inc.’s drug for hemophilia, marking another setback for the company in the treatment of ...

Pfizer Inc. forecast little to no sales growth next year as the drugmaker undertakes an effort to refresh its pipeline of hit drugs with a series of pricey acquisitions.

In a significant move for investors, Brookstone Capital Management has increased its stake in Pfizer Inc. (NYSE:PFE) by a staggering 134.1%, now holding 269,381 shares valued at $6.86 million. This ...

The stock's Price to Earnings ratio of 14.56 is lower than the industry average by 0.24x, suggesting potential value in the ...

Pfizer disclosed a patient death in a marstacimab hemophilia study, triggering a safety review and reassessment of surgical ...

We recently published 12 Stocks on Jim Cramer’s Radar. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer’s radar.

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.

Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 first-quarter 2026 dividend on the company's common stock, payable March 6, 2026, to holders of the Common Stock of ...

In a landscape where pharmaceutical giants are continuously vying for market dominance, Pfizer Inc. has revealed a cautious outlook for the upcoming year, projecting little to no sales growth. This ...

Pfizer Inc. is looking to sell its remaining stake in Covid-19 vaccine partner BioNTech SE, a remnant from one of the pandemic’s most lucrative collaborations. The US drugmaker is offering about 4.55 ...